Proof-of-concept randomised clinical trial (n=30) of psilocybin-enhanced psychotherapy (two oral doses 25–30 mg) versus treatment-as-usual among veterans in residential treatment for methamphetamine use disorder.
Randomised, parallel-group study in veterans admitted to residential rehabilitation comparing psilocybin-enhanced psychotherapy (4 preparatory visits, 2 dosing sessions, 8 integration visits) with treatment-as-usual.
Primary aims are acceptability, feasibility, and safety with primary endpoint at end of intervention; secondary aims assess preliminary efficacy for methamphetamine use disorder and overall functioning at 60- and 180-day follow-ups.
Two psilocybin dosing sessions integrated into a residential psychotherapy protocol (preparation, dosing, integration).
Doses 25–30 mg given two weeks apart; paired with preparatory and integration therapy.
Standard residential rehabilitation programme (behavioural treatment-as-usual).
Behavioural treatment-as-usual provided by residential programme.